drugset
drugset / Trial / NCT03567694

Single and Multiple Doses of HA115 and Food Effect in Healthy Adult Volunteers

NCT03567694 ↗

Phase 1 Withdrawn Conjupro Biotherapeutics, Inc.
RandomizedSequentialQuadruple-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled Phase 1 study of HA115 capsules administered orally to healthy adult volunteers.

Timeline

Start
2021-10-01
Primary completion
2022-10-10
Completion
2022-10-12

Outcome

Outcome not reported

Stopped (Business): “Business decision”

Drugs

EvaluationDrugModalityDoseRoute
Subject HA115 Unknown 10 mg Oral
Subject HA115 Unknown 25 mg Oral
Subject HA115 Unknown 50 mg Oral
Subject HA115 Unknown 100 mg Oral
Subject HA115 Unknown 200 mg Oral
Subject HA115 Unknown 400 mg Oral
Subject HA115 Unknown 800 mg Oral
Subject HA115 Unknown 1200 mg Oral

Indications

asthma